US2004171678A1PendingUtilityA1
Method of treating cancer using dithiocarbamate derivatives
Assignee: CHARLOTTE MECKLENBURG HOSPITALPriority: Sep 8, 1998Filed: Feb 25, 2004Published: Sep 2, 2004
Est. expirySep 8, 2018(expired)· nominal 20-yr term from priority
Inventors:Thomas P. Kennedy
A61K 33/243A61K 33/242A61K 45/06A61K 33/04A61K 33/38A61K 33/26A61K 33/245A61K 31/325A61K 33/32A61K 33/36A61K 33/30A61K 33/34A61K 31/27
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
Claims
exact text as granted — not AI-modifiedThat which is claimed is:
1 . A method of treating cancer in human cells and for sensitizing tumors to conventional cancer chemotherapy by blocking the P-glycoprotein membrane toxin extrusion pump and for sensitizing AIDS patients to anti-retroviral therapy by blocking the P-glycoprotein membrane toxin extrusion pump comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
wherein R 2 and R 3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is an alkali metal selected from the group consisting of from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium; and n is the valence of the alkali metal.
2 . The method according to claim 1 wherein said dithiocarbamate thiolate is in the form of a pharmaceutically acceptable salt.
3 . The method according to claim 1 wherein said dithiocarbamate thiolate is administered in a dosage of between about 125 to about 1000 mg per day of body weight.
4 . The method according to claim 1 wherein said dithiocarbamate thiolate is administered in a dosage of between about 250 to about 500 mg per day.
5 . The method according to claim 1 wherein said dithiocarbamate thiolate is administered parenterally.
6 . The method according to claim 1 wherein said dithiocarbamate thiolate is administered orally.
7 . The method according to claim 1 wherein said dithiocarbamate thiolate is administered in combination with a metal complex that includes a metal selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc, and an ion selected from the group consisting of sodium, potassium, calcium, magnesium, barium, or lithium or an anion of small molecular weight.
8 . The method according to claim 1 wherein said dithiocarbamate thiolate is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.
9 . The method according to claim 7 wherein said metal complex is administered separately as a chelate with an organic anion.
10 . The method according to claim 1 wherein said ion is an organic anion selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.
11 . The method according to claim 1 wherein said dithiocarbamate thiolate is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc, and an ion selected from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium or an anion of small molecular weight.
12 . A method of reducing hypoxic or ischemic damage to the cardiovascular system of a human comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
wherein R 2 and R 3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is an alkali metal selected from the group consisting of from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium; and n is the valence of the alkali metal.
13 . The method according to claim 12 wherein said dithiocarbamate thiolate anion is in the form of a pharmaceutically acceptable salt.
14 . The method according to claim 12 wherein said dithiocarbamate is administered in a dosage of between about 125 to about 1000 mg per day of body weight.
15 . The method according to claim 12 wherein said dithiocarbamate is administered in a dosage of between about 250 to about 500 mg per day for disulfiram.
16 . The method according to claim 12 wherein said dithiocarbamate is administered parenterally.
17 . The method according to claim 12 wherein said dithiocarbamate is administered orally.
18 . The method according to claim 12 wherein said dithiocarbamate is administered in combination with a metal complex that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.
19 . The method according to claim 12 wherein said metal complex is administered separately as a chelate with an organic anion.
20 . The method according to claim 12 wherein said an organic anion is selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.
21 . The method according to claim 12 wherein said dithiocarbamate is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.
22 . A method of reducing hypoxic or ischemic damage to the cardiovascular system of a human comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
wherein R 2 and R 3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is an alkali metal selected from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium; An is a metal selected from the group consisting of titanium, vanadium, chromium, iron, cobalt, nickel, copper, silver, silver, and gold; n is the valence of the metal.
23 . The method according to claim 22 wherein said dithiocarbamate thiolate anion is in the form of a pharmaceutically acceptable salt.
24 . The method according to claim 22 wherein said dithiocarbamate is administered in a dosage of between about 125 to about 1000 mg per day of body weight.
25 . The method according to claim 22 wherein said dithiocarbamate is administered in a dosage of between about 250 to about 500 mg per day for disulfiram.
26 . The method according to claim 22 wherein said dithiocarbamate is administered parenterally.
27 . The method according to claim 22 wherein said dithiocarbamate is administered orally.
28 . The method according to claim 22 wherein said dithiocarbamate is administered in combination with a metal complex that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.
29 . The method according to claim 22 wherein said metal complex is administered separately as a chelate with an organic anion.
30 . The method according to claim 22 wherein said an organic anion is selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.
31 . The method according to claim 22 wherein said dithiocarbamate is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.
32 . A method for treating asthma or arthritis in humans comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
wherein R 2 and R 3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is an alkali metal selected from the group consisting of from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium; and n is the valence of the alkali metal.
33 . The method according to claim 32 wherein said dithiocarbamate thiolate anion is in the form of a pharmaceutically acceptable salt.
34 . The method according to claim 32 wherein said dithiocarbamate is administered in a dosage of between about 125 to about 1000 mg per day of body weight.
35 . The method according to claim 32 wherein said dithiocarbamate is administered in a dosage of between about 250 to about 500 mg per day for disulfiram.
36 . The method according to claim 32 wherein said dithiocarbamate is administered parenterally.
37 . The method according to claim 32 wherein said dithiocarbamate is administered orally.
38 . The method according to claim 32 wherein said dithiocarbamate is administered in combination with a metal complex that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.
39 . The method according to claim 32 wherein said metal complex is administered separately as a chelate with an organic anion.
40 . The method according to claim 32 wherein said an organic anion is selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.
41 . The method according to claim 32 wherein said dithiocarbamate is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.
42 . A method for treating asthma or arthritis in humans comprising administering a therapeutically effective amount of a dithiocarbamate thiolate anion of the formula:
wherein R 2 and R 3 are the same or different and represent hydrogen, and unsubstituted or substituted alkyl, akenyl, aryl, alkoxy, and heteroaryl groups; M is an alkali metal selected from the group consisting of sodium, potassium, calcium, magnesium, barium, and lithium; An is a metal selected from the group consisting of titanium, vanadium, chromium, iron, cobalt, nickel, copper, silver, silver, and gold; n is the valence of the metal.
43 . The method according to claim 42 wherein said dithiocarbamate thiolate anion is in the form of a pharmaceutically acceptable salt.
44 . The method according to claim 42 wherein said dithiocarbamate is administered in a dosage of between about 125 to about 1000 mg per day of body weight.
45 . The method according to claim 42 wherein said dithiocarbamate is administered in a dosage of between about 250 to about 500 mg per day for disulfiram.
46 . The method according to claim 42 wherein said dithiocarbamate is administered parenterally.
47 . The method according to claim 42 wherein said dithiocarbamate is administered orally.
48 . The method according to claim 42 wherein said dithiocarbamate is administered in combination with a metal complex that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.
49 . The method according to claim 42 wherein said metal complex is administered separately as a chelate with an organic anion.
50 . The method according to claim 42 wherein said an organic anion is selected from the group consisting of citrate, acetate, glyconate, glycinate, propionate and lactate.
51 . The method according to claim 42 wherein said dithiocarbamate is administered in combination with a metal chelate that includes an ion selected from the group consisting of arsenic, bismuth, cobalt, copper chromium, gallium, gold iron, manganese, nickel, silver, titanium, vanadium, selenium and zinc.Join the waitlist — get patent alerts
Track US2004171678A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.